TMO EPM / Hemato H9J
TMO EPM / Hemato H9J
Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA
Autor
TMO EPM / Hemato H9J
Kategorie
Podcast-Website
Neueste Folge
6. Jul 2026
Wo hören?
Podcasts in der App Replaio Radio Bald verfügbarPodcasts kommen bald in die App. Installiere sie jetzt und erlebe als Erster einen ganz neuen Blick auf Podcasts
Kostenlos installieren
Android fast 10 Mio. Downloads · Bewertung 4,8
iOS bald
Folgen
27 - Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma 14.04.2024 30:58
Discussão do artigo: "Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma" de Koji Kato Bone Marrow Transplantation 2024 Apresentado por: Dra Aline Guerra Discussão por: Dra. Camila Ferreira, Dr. Rafael Faust, Dr. Matheus Puls, Dr. Pedro Arruda e Dr. Vinicius Molla
26 - Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 06.04.2024 30:58
Discussão do artigo: "Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3" de Levis M J Clin Oncol 2024 Apresentado por: Dra Marcella Markman Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Matheus Puls, Dr. Gabriel Coquito, Dr. Pedro Arruda e Dr. Vinicius Molla.
25 - PTCy versus ATG after RIC peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors 28.03.2024 32:44
Discussão do artigo: "PTCy versus ATG after RIC peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial" de Brissot E Blood Cancer Journal 2024 Apresentado por: Dra Thaís Araújo Discussão por: Dra. Camila Ferreira, Dr. Rafael Faust, Dr. Pedro Arruda,...
24 - Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study 25.03.2024 30:06
Discussão do artigo: "Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study" de Bazinet A Lancet Haematol 2024 Apresentado por: Dr Gabriel Coquito Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dra. Aline Guerra, Dr. Pedro Arruda e Dr. Vinicius Molla.
23 - Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up 16.03.2024 24:51
Discussão do artigo: "Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up" de Dimopoulos M Lancet Haematol 2023 Apresentado por: Dra Luana Pompeu Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Gabriel Coquito, Dr. Pedro Arruda, Dr. Vinicius M...
22 - Tacrolimus /methotrexate vs tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease prevention 03.03.2024 27:51
Discussão do artigo: "Tacrolimus /methotrexate vs tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease prevention" de Hamilton B Blood advances 2023 Apresentado por: Dr. Carlos Rivera Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Diego Luz, Dra. Fernanda Azevedo, Dr. Eurides Rosa, Dr. Caio Justino e Dr. Vinicius Molla.
21 - Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids 29.02.2024 26:33
Discussão do artigo: "Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids" de Oluwole O BMT 2024 Apresentado por: Dr. Caio Prato Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Eurides Rosa, Dr. Pedro Arruda e Dr. Vinicius Molla.
20 - Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML 17.02.2024 30:50
Discussão do artigo: "Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML" de Short NJ J Clin Oncol 2024 Jan 26 Apresentado por: Dra. Fernanda Azevedo Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Caio Prato, Dra. Eurides Rosa, Dr. Pedro Arruda e Dr. Vinicius Molla.
19 - Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study 04.02.2024 27:33
Discussão do artigo: "Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study" de Dimopoulos M JCO 2023. Apresentado por: Dr. Pedro Flores Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Diego Luz, Dr. Pedro Arruda e Dr. Vinicius Molla.
18 - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma 29.01.2024 36:37
Discussão do artigo: "Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma" de Sonneveld P NEJM 2023 Apresentado por: Dr. Pedro Flores Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Diego Luz, Dra. Fernanda Azevedo, Dra. Roberta Szor, Dr. Pedro Arruda e Dr. Vinicius Molla.
17 - Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease 14.01.2024 26:52
Discussão do artigo: "Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease" de Munir t NEJM 2023. Apresentado por: Dr. Diego Luz Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Pedro Flores, Dr. Pedro Arruda e Dr. Vinicius Molla.
16 - Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AML 17.12.2023 34:15
Discussão do artigo: "Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AML" de Grob t Clin Oncol 41:756-765. Apresentado por: Dra. Fernanda Azevedo Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Caio Prato, Dr. Pedro Flores, Dr. Diego Luz, Dr. Eurides Rosa, Dr. Pedro Arruda e Dr. Vinicius Molla.
15 - Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation 03.12.2023 26:39
Discussão do artigo: "Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation" de Yang L BMT 2023. Apresentado por: Dra. Nicole Marques Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Caio Prato, Dr. Carlos Rivera, Dr. Pedro Arruda e Dr. Vinicius Molla.
14 - BuFlu vs BuCy for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial 26.11.2023 28:51
Discussão do artigo: "BuFlu vs BuCy for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial" de Ling Y J Clin Oncol 2023 41:4632-4642 Apresentado por: Dr. Pedro Flores Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Diego Luz, Dra. Nicole Marques, Dr. Pedro Arruda, Dr. Vinicius Molla e Dr. Eurides Rosa.
13 - R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma 19.11.2023 28:40
Discussão do artigo: " R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma " de Chamuleau MED Lancet Haematol 2023 Apresentado por: Dr. Diego Luz Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Diego Luz, Dr. Pedro Flores, Dr. Pedro Arruda, Dr. Vinicius Molla, Dr. Eurides Rosa e Dr. Celso Arrais.
12 - PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation 13.11.2023 42:48
Discussão do artigo: " PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation " de Al-Homsi A Blood Adv (2023) 7 (14): 3604–3611. Apresentado por: Dr. Carlos Rivera Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Diego Luz, Dr. Pedro Arruda, Dr. Vinicius Molla e Dr. Eurides Rosa.
11 - Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER) 22.10.2023 34:25
Discussão do artigo: " Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER) " de Costa L, Lancet Haematol 2023. Apresentado por: Dra. Fernanda Azevedo Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Caio Prato, Dr. Pedro Arruda, Dr. Vinicius Molla e Dr. Celso Arrais.
10 - Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma 08.10.2023 32:18
Discussão do artigo: " Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma " de Rodriguez‐Otero P, N Engl J Med 2023;388:1002-14 Apresentado por: Dr. Diego Luz Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dra. Thais Araujo, Dra. Fernanda Azevedo, Dr. Pedro Arruda e Dra. Roberta Szor.
09 - Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis 02.10.2023 27:33
Discussão do artigo: " Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis " de Hernani R, eJHaem. 2021;2:236–248 Apresentado por: Dr. Carlos Rivera Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dra. Fernanda Azevedo, Dr. Pedro Arruda e Dr. Vinícius Mo...
08 - Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL 24.09.2023 24:47
Discussão do artigo: " Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL " de Tisi M, Blood Adv (2023) 7 (15): 3916–3924. Apresentado por: Dr. Caio Prato Discussão por: Dr. Celso Arrais, Dr. Breno Aires, Dr. Pedro Flores, Dr. Pedro Arruda e Dr. Vinícius Molla.
07 - Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients 28.08.2023 23:22
Discussão do artigo: " Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients " de Beelen D, Am J Hematol. 2022;97:1023–1034. Apresentado por: Dra. Nicole Marques Discussão por: Breno Aires, Thais Araujo, Ana Paula Tavares, Pedro Arruda, e Vinícius Molla.
06 - Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma 19.08.2023 31:17
Discussão do artigo: "Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma" de Jason R. Westin, N Engl J Med 2023; 389:148-157 Apresentado por: Dr. Pedro Flores Discussão por: Camila Ferreira, Matheus Puls, Nicole Marques, Pedro Arruda, Roberta Szor e Vinícius Molla.
05 - Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD AML: long-term follow-up of an open-label, multicentre, randomised, phase 3 12.08.2023 31:11
Discussão do artigo: " Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial " de Xuan L, Lancet Haematol 2023; 10: 600–11. Apresentado por: Caio Prato Discussão por: Breno Aires, Fernanda Azevedo, Thais Araujo, Pedro Flores, Pedro Arruda...
04 - Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 05.08.2023 32:25
Discussão do artigo: " Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 " de Stephan A Grupp, Lancet Haematol, March 28, 2023. Apresentado por: Fernanda Azevedo Discussão por: Camila Ferreira, Celso Arrais, Matheus Puls, Thais Fernanda, Pedro Arruda e Viníci...
03 - Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) 29.07.2023 25:58
Discussão do artigo: " Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) " de Esther Natalie Oliva, Journal of Clinical Oncology 2023. Apresentado por: Nicole Marques Discussão por: Breno Aires, Diego Luz, Matheus Puls, Pedro Flores, Thais Fernanda, Pedro Arruda e Vinícius Moll...
Ähnliche Podcasts
Höre den Podcast TMO EPM / Hemato H9J in Replaio
Radio und Podcasts in einer App - kostenlos und ohne Anmeldung. Installiere sie noch heute und verpasse den Start nicht
Replaio ist kein Herausgeber von Podcasts; die Namen der Sendungen, Cover und Audioinhalte gehören ihren Autoren und werden über öffentliche RSS-Feeds verbreitet
